Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A, Hussein MA, Reu FJ, Faiman B, Habecker B, Ann Karam M, Reed J, Hamilton K, Waksman J, Bruening K, Srkalovic G, Andresen S, Kalaycio M, Sweetenham JW, Sobecks R, Dean R, Knight R, Zeldis JB, Baz R. Lazaryan A, et al. Am J Hematol. 2014 Apr;89(4):349-54. doi: 10.1002/ajh.23639. Epub 2014 Feb 24. Am J Hematol. 2014. PMID: 24273135 Free article. Clinical Trial.
Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry.
Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Gillis N, et al. Among authors: lazaryan a. Transplant Cell Ther. 2023 Oct;29(10):640.e1-640.e8. doi: 10.1016/j.jtct.2023.07.021. Epub 2023 Jul 28. Transplant Cell Ther. 2023. PMID: 37517612
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease.
Ibrahim U, Bassil C, Chavez JC, Khimani F, Jain MD, Locke FL, Osman K, Lazaryan A. Ibrahim U, et al. Among authors: lazaryan a. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):772-778. doi: 10.1016/j.clml.2023.05.007. Epub 2023 May 12. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37263876 No abstract available.
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study.
Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Lee DH, et al. Among authors: lazaryan a. Cardiooncology. 2023 Apr 1;9(1):18. doi: 10.1186/s40959-023-00170-5. Cardiooncology. 2023. PMID: 37005652 Free PMC article.
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide.
Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Elmariah H, et al. Among authors: lazaryan a. Transplant Cell Ther. 2024 Feb;30(2):229.e1-229.e11. doi: 10.1016/j.jtct.2023.11.010. Epub 2023 Nov 11. Transplant Cell Ther. 2024. PMID: 37952648 Clinical Trial.
Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).
Bejanyan N, Bolwell BJ, Lazaryan A, Rybicki L, Tench S, Duong H, Andresen S, Sobecks R, Dean R, Pohlman B, Kalaycio M, Copelan EA. Bejanyan N, et al. Among authors: lazaryan a. Biol Blood Marrow Transplant. 2012 Jun;18(6):874-80. doi: 10.1016/j.bbmt.2011.10.032. Epub 2011 Oct 29. Biol Blood Marrow Transplant. 2012. PMID: 22040844 Free article.
107 results